aspirin has been researched along with Non-alcoholic Fatty Liver Disease in 15 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Many basic mechanistic studies found that aspirin inhibited multiple pathways involved in non-alcoholic fatty liver disease (NAFLD) development." | 7.80 | Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. ( Bostick, RM; Jawairia, M; Mustacchia, P; Shahzad, G; Shen, H, 2014) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 5.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval." | 5.48 | Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet." | 5.37 | Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011) |
| "Many basic mechanistic studies found that aspirin inhibited multiple pathways involved in non-alcoholic fatty liver disease (NAFLD) development." | 3.80 | Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. ( Bostick, RM; Jawairia, M; Mustacchia, P; Shahzad, G; Shen, H, 2014) |
| "Nonalcoholic steatohepatitis is a common finding in patients with CVD." | 2.80 | PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. ( Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A, 2015) |
| "Animals without steatosis (ie NAFLD) at week 16 were excluded from the data analysis." | 1.62 | The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis. ( Andersen, M; Buelund, LE; Ipsen, DH; Latta, M; Lintrup, K; Lykkesfeldt, J; Skaarup, R; Skat-Rørdam, J; Svenningsen, M; Tveden-Nyborg, P, 2021) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 1.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is now a public health issue worldwide, but no drug has yet received approval." | 1.48 | Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A ( Chen, J; Chen, W; Li, H; Mao, J; Wang, M; Wang, W; Zhang, H, 2018) |
| "The degree of liver fibrosis was determined using four validated fibrosis indices and a composite index." | 1.43 | Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. ( Afdhal, N; Feldbrügge, L; Ghaziani, T; Jiang, ZG; Mukamal, KJ; Popov, Y; Robson, SC; Tapper, EB, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet." | 1.37 | Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. ( Abdelrahman, AM; Farghaly, E; Gomaa, W; Ibrahim, M; Kelleni, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ramandi, A | 1 |
| George, J | 1 |
| Merat, S | 2 |
| Jafari, E | 2 |
| Sharafkhah, M | 1 |
| Radmard, AR | 2 |
| Nateghi Baygi, A | 1 |
| Delavari, A | 1 |
| Mohammadi, Z | 1 |
| Poustchi, H | 2 |
| Malekzadeh, R | 2 |
| Severo, MD | 1 |
| Han, YM | 1 |
| Lee, YJ | 1 |
| Jang, YN | 1 |
| Kim, HM | 1 |
| Seo, HS | 1 |
| Jung, TW | 1 |
| Jeong, JH | 1 |
| Ipsen, DH | 1 |
| Skat-Rørdam, J | 1 |
| Svenningsen, M | 1 |
| Andersen, M | 1 |
| Latta, M | 1 |
| Buelund, LE | 1 |
| Lintrup, K | 1 |
| Skaarup, R | 1 |
| Lykkesfeldt, J | 1 |
| Tveden-Nyborg, P | 1 |
| Wang, W | 1 |
| Chen, J | 1 |
| Mao, J | 1 |
| Li, H | 2 |
| Wang, M | 1 |
| Zhang, H | 1 |
| Chen, W | 1 |
| Zhou, Y | 1 |
| Peng, H | 1 |
| Liu, Z | 1 |
| Zhang, KK | 1 |
| Jendrusch, C | 1 |
| Drake, M | 1 |
| Hao, Y | 1 |
| Xie, L | 1 |
| Simon, TG | 2 |
| Henson, J | 1 |
| Osganian, S | 1 |
| Masia, R | 1 |
| Chan, AT | 1 |
| Chung, RT | 1 |
| Corey, KE | 2 |
| Vilar-Gomez, E | 1 |
| Chalasani, N | 1 |
| Shen, H | 1 |
| Shahzad, G | 1 |
| Jawairia, M | 1 |
| Bostick, RM | 1 |
| Mustacchia, P | 1 |
| Armstrong, MJ | 1 |
| Rowe, IA | 1 |
| Hemming, K | 1 |
| Nateghi, A | 1 |
| Shiravi Khuzani, A | 1 |
| Khoshnia, M | 1 |
| Marshall, T | 1 |
| Jiang, ZG | 1 |
| Feldbrügge, L | 1 |
| Tapper, EB | 1 |
| Popov, Y | 1 |
| Ghaziani, T | 1 |
| Afdhal, N | 1 |
| Robson, SC | 1 |
| Mukamal, KJ | 1 |
| Ibrahim, M | 1 |
| Farghaly, E | 1 |
| Gomaa, W | 1 |
| Kelleni, M | 1 |
| Abdelrahman, AM | 1 |
| Russo, MW | 1 |
| Pierson, J | 1 |
| Narang, T | 1 |
| Montegudo, A | 1 |
| Eskind, L | 1 |
| Gulati, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fixed-dose Combination Therapy (PolyPill) in Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians - Focus on Liver-Related Variables.[NCT01245608] | Phase 3 | 2,400 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for aspirin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.
Topics: Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Non-alcoholic Fatty Liver Disease; Pros | 2023 |
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; | 2015 |
13 other studies available for aspirin and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Daily Aspirin Use Associated With Reduced Risk for Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease.
Topics: Aspirin; Disease Progression; Fibrosis; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2020 |
Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPAR
Topics: AMP-Activated Protein Kinases; Animals; Aspirin; Atherosclerosis; Dyslipidemias; Hep G2 Cells; Human | 2020 |
The effect of acetylsalicylic acid and pentoxifylline in guinea pigs with non-alcoholic steatohepatitis.
Topics: Animals; Aspirin; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Reposit | 2021 |
Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Diet, High-Fat; Disease Models, Animal; Disease Progres | 2018 |
Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Diet, High-Fat; Female; Gluc | 2019 |
Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Aspirin; Cohort Studies; Disease Progression; Duration of | 2019 |
Daily Aspirin Use Reduces Risk of Fibrosis Progression in Patients With Nonalcoholic Fatty Liver Disease, Providing New Uses for an Old Drug.
Topics: Aspirin; Disease Progression; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2019 |
Reply.
Topics: Aspirin; Disease Progression; Fibrosis; Humans; Non-alcoholic Fatty Liver Disease | 2020 |
Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Female; Huma | 2014 |
Editorial: would an aspirin a day keep NAFLD and its complications away?
Topics: Aspirin; Female; Humans; Male; Non-alcoholic Fatty Liver Disease; Nutrition Surveys | 2015 |
Aspirin use is associated with lower indices of liver fibrosis among adults in the United States.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Female; Hepatitis, | 2016 |
Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Aspirin; Cyclooxygenase 2; Fatty Liver; Gene Expression Regulation, E | 2011 |
Coronary artery stents and antiplatelet therapy in patients with cirrhosis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Fatty Liver; Female; Follow-Up Studies; Gastroi | 2012 |